Don’t miss the latest developments in business and finance.

Glenmark Pharma launches Travoprost Ophthalmic Solution USP

Image
Last Updated : Nov 27 2024 | 9:31 AM IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution).

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc.

According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Nov 27 2024 | 9:12 AM IST

Next Story